Tomorrow the trial we are all waiting for at #AHA25 is VESALIUS-CV Trial #VESALIUSCV is the first trial to test a PCSK9 inhibitor for people who’ve never had a heart attack or stroke: moving lipid therapy deeper into primary prevention 📍top line results already released: in 12,000 high-risk adults without prior MI or stroke, adding Evolocumab (140 mg q2 wks) to optimized lipid-lowering therapy for ~4.5 yrs cut major CV events #HeartHealth #CVPrev #lipids #PCSK9i